NASDAQ$RYTM

Rhythm Pharmaceuticals Inc · Q1 2024 earnings

Q1 2024 earnings · · Investor relations

Briefing

RYTM Q1 2024 — $200.0M revenue

The results for the three months ended March 31, 2024 are not necessarily indicative of the results expected for the full fiscal year, any other interim periods, or any future year or period. Rhythm Pharmaceuticals Inc reported Q1 2024 results. Net income of $141.4M. Headline numbers extracted from the Form 10-Q press release; narrative is light because this row was processed without an LLM call.

  • Revenue: $200.0M.
  • Net income: $141.4M.
  • Filed on Form 10-Q (accession 0001558370-24-007076).

Headline financials

Total Revenue

$26M

Previous: $11.5M+126.4%
EPS

-$2.35

Previous: -$0.92-155.4%
Capital Expenditures

-$47K

Previous: -$47K+0.0%
Free Cash Flow

-$141M

Previous: -$52.2M-170.8%
Net Income

-$141M

Previous: -$52.2M-170.9%
Operating Income

-$140M

Previous: -$52.5M-166.3%
Gross Profit

$23.2M

Previous: $10M+130.5%
R&D Expense

$129M

No prior period
Stock-Based Comp

$7.77M

Previous: $6.38M+21.8%

Revenue & EPS history

Rhythm Pharmaceuticals · Revenue · Quarterly

$26M

Q1 2024+126.4%vs Q1 2023
Beat estimate in 6 of 15 quarters(40%)
ActualEstimate

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q1 2024

Historical avgQ1 2024

+3.1%

Avg return

Earnings day

+2.4%

Avg return

5 days after

+5.4%

Avg return

30 days after

53%

18 / 34 earnings

Positive

+40.8%

Q2 2022

Best reaction

-15.7%

Q2 2021

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+8.2%+10.3%+2.5%
Q4 2025-0.9%-9.7%-23.5%
Q3 2025-7.7%-11.8%-7.1%
Q1 2025+2.9%-6.0%+8.6%
Q4 2024+4.5%+2.7%+7.4%
Q3 2024+18.2%+27.1%+9.1%
Q2 2024-1.1%+2.8%+9.6%
Q1 2024-11.3%-10.8%-9.6%
Q4 2023-7.5%-5.7%-16.9%
Q3 2023+1.2%+5.1%+40.3%
Q2 2023+36.3%+37.0%+45.8%
Q1 2023-8.4%-17.4%-15.0%
Q4 2022+0.1%-9.8%-26.6%
Q3 2022-2.5%+15.5%+15.7%
Q2 2022+40.8%+62.6%+103.5%
Q1 2022-12.5%-32.1%-46.0%
Q4 2021+21.3%+21.7%+51.2%
Q3 2021+14.4%+14.9%-24.0%
Q2 2021-15.7%-17.5%-22.1%
Q1 2021-0.1%+2.6%-10.5%
Q4 2020+3.2%+0.2%-17.9%
Q3 2020+8.8%+7.9%+51.2%
Q2 2020-2.4%-1.8%+55.2%
Q1 2020+7.1%+8.7%+10.9%
Q4 2019+3.0%-5.4%-22.1%
Q3 2019+0.6%-1.3%+5.3%
Q2 2019-4.7%-2.9%+11.7%
Q1 2019-0.7%-1.0%-2.4%
Q4 2018+5.8%+8.2%+1.6%
Q3 2018-12.3%-15.3%-13.1%
Q2 2018-1.3%-2.8%-5.9%
Q1 2018+17.8%+21.2%+29.9%
Q4 2017+6.9%-16.3%-24.0%
Q3 2017-5.7%+1.3%+10.1%
Q2 2017
Q1 2017
Q4 2016
Q3 2016
Q2 2016
Q1 2016
Q4 2015
Q3 2015
Q2 2015
Q1 2015
Q4 2014
Q3 2014
Q2 2014
Q1 2014

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro